Figure 5.

Combined treatment with MG132 and cisplatin inhibited tumor growth in HOS xenograft mouse model. HOS cells (1 × 10⁷) were suspended in 200 μl of PBS and subcutaneously injected into the right flanks of the nude mice. When the tumors were visible, the mice were randomly divided into four groups (n = 5): control (0.2 ml of PBS), MG132 (2 mg/kg), cisplatin (2 mg/kg), and combination group (MG132: 2 mg/kg + 2 mg/kg). The mice were intraperitoneally injected with the above reagents every 3 days for 15 days. (A) Tumor volume was measured every 2 days using a caliper. *p < 0.05 versus control (PBS) denotes a significant difference, #p < 0.05 versus MG132 or cisplatin denotes a significant difference. (B) At the end, mice were sacrificed, and tumors were removed and weighed. *p < 0.05 versus control (PBS) denotes a significant difference, #p < 0.05 versus MG132 or cisplatin denotes a significant difference. (C) Mice body weights were measured once a week and were used as an indicator of the systemic toxicity of the treatment.